Sartorius Polyplus is a leading upstream solutions provider for advanced biological and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help customers (or the industry) optimize process economics while meeting strict scientific and regulatory standards.
We wanted to share that we will not be actively posting or engaging on this LinkedIn account. However, you can continue to stay updated and connect with us over https://www.linkedin.com/showcase/106511553
We appreciate all the conversations and connections we’ve built here and look forward to continuing them on our other page.
Thank you for your support, and we hope to see you there!
Company Details
- Employees
- 112
- Address
- Vectura, 75 Rue Marguerite Perey,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- polyplus-transfection.com
- Keywords
- Research, DNA, Transfection, Gene expression, Bioproduction, Life sciences, Biotechnology, RNA interference, Science, Biology, Protein production, Virus production, Cell culture, CRISPR, Biotechnology.
- HQ
- ILLKIRCH GRAFFENSTADEN
Sartorius Polyplus Questions
Sartorius Polyplus's website is polyplus-transfection.com
Sartorius Polyplus's LinkedIn profile is https://fr.linkedin.com/company/polyplus-sartorius
Sartorius Polyplus has
112 employees.
View email and phone details for 112
employees at Sartorius Polyplus.
Sartorius Polyplus's industry is
Biotechnology Research
Sartorius Polyplus's top competitors are
Inoviem Scientific,
Polypeptide Group,
Proteogenix,
Sartorius Xpress Biologics,
Domain Therapeutics,
Sartorius | Bioprocess Solutions,
Novalix,
Sartorius,
Transgene,
Biosynex Pharma.
Sartorius Polyplus's categories are Biotechnology Research
